The 5 billion antihypertensive drug market has ushered in strong competitors

Recently, Guangzhou Poinsettia Pharmaceuticals issued an announcement stating that its valsartan oral solution, which was reported to be produced as a generic class 3 product, has entered the stage of administrative approval
.
It is understood that Poinsettia is a pharmaceutical innovation enterprise focusing on drug research and development, production and sales.
Its products focus on the fields of children's drugs and chronic disease drugs, mainly engaged in the research and development, production and sales of prescription drugs
.
In recent years, Poinsettia has been accelerating the enrichment of the company's product pipeline and categories, enhancing the company's competitiveness in the field of chronic diseases
.
It is expected in the industry that if the valsartan oral solution can be successfully launched, it may become the first domestic valsartan oral solution product
.
According to the data, valsartan is a commonly used antihypertensive drug in clinical practice
.
The original manufacturer of this product is Novartis, which was approved for marketing in the United States in July 2001.
It is mainly used for the treatment of mild to moderate essential hypertension
.
At present, with the intensification of population aging and the influence of factors such as life and diet, the scale of cardiovascular disease and other related drugs in the retail market is gradually expanding, and it has exceeded the 20 billion yuan mark in 2019
.
It can also be seen that the market potential of valsartan products will be huge
.
It is understood that due to the impact of the epidemic and centralized procurement, the terminal sales of valsartan in China's public medical institutions will decline by 10.
47% in 2020, but the terminal sales of physical pharmacies in Chinese cities will not decline but rise
.
Data shows that the terminal sales of valsartan in Chinese public medical institutions and Chinese urban physical pharmacies in 2020 will total more than 5 billion yuan; in 2021, the terminal sales in Chinese urban physical pharmacies are expected to increase by 3.
57%
.
In this context, if Poinsettia valsartan oral solution is successfully launched, it is expected that the sales will be very impressive
.
This is mainly due to the fact that the current valsartan products are in oral liquid preparations, and no company has yet been approved for marketing
.
However, it should be noted that in addition to Guangzhou Yiyihong, Changzhou No.
4 Medicines have also submitted 3 types of generic marketing applications for valsartan oral solution.

.
Last year, the registration status of Changzhou No.
4 Pharmaceuticals' product has been changed to "under approval".
There are still certain variables in who will pass the evaluation first in the future
.
It is worth noting that, in addition to valsartan oral liquid, the tablets, dispersible tablets and capsules of valsartan products are all available on the market
.
At present, in these fields, there are still many enterprises that are still accelerating their deployment
.
For example, some time ago, Yongxin Pharmaceuticals announced that the company has recently received the "Approval Notice for Supplementary Drug Application" issued by the State Drug Administration (hereinafter referred to as the "NMPA") for Valsartan Capsules ( Notification No.
: 2022B00073), the drug was approved to pass the quality and efficacy consistency evaluation of generic drugs
.
In addition, in terms of valsartan tablets, Guangzhou Yipinhong Pharmaceutical Co.
, Ltd.
has also recently received the "Drug Registration Certificate" approved and issued by the State Drug Administration.
The generic name of the drug is Valsartan Amlodipine Tablets (I)
.
The drug will be used in patients whose blood pressure cannot be adequately controlled with monotherapy
.
From the above point of view, the industry believes that the market competition for valsartan products will be very fierce in the future
.